Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.
Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Mardekian J, Borham A, George DJ, Harrison MR. Costello BA, et al. Among authors: mardekian j. Clin Genitourin Cancer. 2022 Feb;20(1):1-10. doi: 10.1016/j.clgc.2021.07.002. Epub 2021 Jul 10. Clin Genitourin Cancer. 2022. PMID: 34364796 Free PMC article.
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: mardekian j. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1032-1040. doi: 10.1038/s41391-021-00318-3. Epub 2021 Feb 21. Prostate Cancer Prostatic Dis. 2021. PMID: 33612825 Free PMC article.
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HSL, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Inman BA, Mardekian J, Borham A, George DJ. Harrison MR, et al. Among authors: mardekian j. Cancer. 2021 Jul 1;127(13):2204-2212. doi: 10.1002/cncr.33494. Epub 2021 Mar 25. Cancer. 2021. PMID: 33765337 Free PMC article.
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: mardekian j. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):800-801. doi: 10.1038/s41391-021-00401-9. Prostate Cancer Prostatic Dis. 2022. PMID: 35039606 Free PMC article. No abstract available.
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: mardekian j. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):804. doi: 10.1038/s41391-022-00578-7. Prostate Cancer Prostatic Dis. 2022. PMID: 35840724 Free PMC article. No abstract available.
160 results